Bioactive Flavonoids in Protecting Against Endothelial Dysfunction and Atherosclerosis

Yin, Yanjun; Xu, Jingjing; Ilyas, Iqra; Xu, Suowen

doi:10.1007/164_2024_715

Handbook of Experimental Pharmacology

2024

DOI: 10.1007/164_2024_715

|View full text |Cite

Bioactive Flavonoids in Protecting Against Endothelial Dysfunction and Atherosclerosis

Yanjun Yin,

Jingjing Xu,

Iqra Ilyas

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1): A Potential Therapeutic Target in Ischemic Stroke

Hu,

Li,

Luo

et al. 2024

Transl. Stroke Res.

View full text Add to dashboard Cite

Stroke, the leading cause of disability and the second leading cause of death worldwide, is characterized by high morbidity and disability. The lectin-like oxidized low-density lipoprotein receptor (LOX-1) is a scavenger receptor that promotes endothelial dysfunction by recognizing and internalizing oxidized low-density lipoproteins (ox-LDL) to induce the formation, development, and instability of atherosclerotic plaques, ultimately leading to vascular thrombosis. Previous clinical and epidemiological studies have indicated that LOX-1 plays a vital role in cerebral ischemic injury following ischemic stroke. Multiple clinical studies have shown that the genetic polymorphisms in LOX-1 are associated with susceptibility to ischemic stroke. Soluble LOX-1 (sLOX-1), a biomarker of ischemic stroke, is associated with the prognosis of ischemic stroke. This article discusses the clinical and experimental findings on LOX-1 in ischemic stroke and the development of new therapeutic strategies targeting LOX-1.

show abstract

Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1): A Potential Therapeutic Target in Ischemic Stroke

Hu,

Li,

Luo

et al. 2024

Transl. Stroke Res.

View full text Add to dashboard Cite

show abstract

Taoren Honghua Decoction alleviates atherosclerosis by inducing autophagy and inhibiting the PI3K-AKT signaling pathway to regulate cholesterol efflux and inflammatory responses

Chang,

Feng,

et al. 2025

International Immunopharmacology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Bioactive Flavonoids in Protecting Against Endothelial Dysfunction and Atherosclerosis

Cited by 2 publications

References 179 publications

Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1): A Potential Therapeutic Target in Ischemic Stroke

Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1): A Potential Therapeutic Target in Ischemic Stroke

Taoren Honghua Decoction alleviates atherosclerosis by inducing autophagy and inhibiting the PI3K-AKT signaling pathway to regulate cholesterol efflux and inflammatory responses

Contact Info

Product

Resources

About